AIM: OF STUDY: To assess the prevalence of insulin antibodies (IA-A) and their binding capacity (c%IA-A) in Type-2 diabetic patients and relation of IA-A/c%IA-A to duration of diabetes, type of therapy, kind/dosage of administered insulin, glycaemic control and to appearance of hypoglycaemic episodes.
SUBJECTS: 196 hospitalised patients with type-2 diabetes mellitus (negative for antiGAD-Ab). Assessed parameters: age, duration of diabetes mellitus, duration of insulin-therapy, BMI, glycaemic profile, IRI, C-peptide, IA-A and antiGAD-Ab (Cis bio international, distr. fy Solupharm).

RESULTS: Prevalence of IA-A and their c%IA-A were related to treatment with insulin. c%IA-A correlated significantly with fasting plasma glucose and IRI concentrations. c%IA-A did not correlate with insulin dosages, C-peptide, BMI, nor with age.

CONCLUSION: Prevalence of IA-A and their c%IA-A in patients with Type-2 diabetes affects levels of total plasma insulin, insulin kinetic and consequently the quality of glycaemic compensation. Prevalence of IA-A is related to duration of insulin therapy, but independent on dosage of administered insulin.

Keywords: Aged; Blood Glucose /analysis/; C-Peptide /blood/; Diabetes Mellitus, Type 2 /immunology/; Humans; Insulin Antibodies /blood/